Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Dabigatran Etexilate in Children with Venous Thromboembolism: Results of the Open-Label, Phase IIb/III, Randomized Diversity Clinical Trial

Jacqueline Halton, MD, Leonardo R. Brandao, MD, Matteo Luciani, MD, Lisa Bomgaars, MD, Elizabeth Chalmers, MD, Lesley Mitchell, MD, Ildar Nurmeev, MD, Anjali Sharathkumar, MD, Pavel Svirin, MD, Kirill Gorbatikov, MD, Igor Tartakovsky, MD, Monika Simetzberger, DI, Fenglei Huang, PhD, Zhichao Sun, PhD, Jörg Kreuzer, MD, Savion Gropper, MD, Martina Brueckmann, MD, Manuela Albisetti, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-136682

Published: 2020

Journal Articles

Efficacy and Safety of Dabigatran in the Treatment and Secondary Prophylaxis of Children with Venous Thromboembolism and Thrombophilia

Leonardo R. Brandao, MD, Igor Tartakovsky, MD, Manuela Albisetti, MD, Lisa Bomgaars, MD, Elizabeth Chalmers, MD, Lesley Mitchell, MD, Matteo Luciani, MD, Paola Saracco, MD, Judy Felgenhauer, MD, Olga Lvova, MD, Monika Simetzberger, DI, Zhichao Sun, PhD, Ingrid Gergei, MD, Martina Brueckmann, MD, Jacqueline Halton, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-136695

Published: 2020

Journal Articles

Pharmacokinetics (PK) and Pharmacodynamics (PD), Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Etexilate Given after Standard Anticoagulant Therapy in Children from Birth to Less Than One Year Old, with Venous Thromboembolism

Jacqueline ML Halton, MD, Anne-Caroline Picard, Ruth Harper, Fenglei Huang, Martina Brueckmann, MD, Savion Gropper, MD, Hugo Maas, Igor Tartakovsky, MD, Ildar Nurmeev, Lesley G Mitchell, Leonardo R. Brandão, MD MSc, Manuela Albisetti, MD

Blood (2016) 128 (22): 1441.

https://doi.org/10.1182/blood.V128.22.1441.1441

Published: 2016

Journal Articles

Rationale and Design of a Phase III Safety Trial of Idarucizumab in Children Receiving Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism

Manuela Albisetti, MD, Arno Schlosser, MSc, Martina Brueckmann, MD, Savion Gropper, MD, Stephan Glund, PhD, Igor Tartakovsky, MD, Leonardo R. Brandão, MD MSc, Paul A Reilly, PhD

Blood (2016) 128 (22): 5010.

https://doi.org/10.1182/blood.V128.22.5010.5010

Published: 2016

Journal Articles

Rationale and Design of a Phase IIb/III Open-Label, Multicenter Study of Dabigatran Etexilate for Venous Thromboembolism in Children: The Diversity Study

Manuela Albisetti, MD, Ivan Manastirski, Martina Brueckmann, MD, Savion Gropper, MD, Bushi Wang, Igor Tartakovsky, MD, Branislav Biss, Fenglei Huang, Lesley G Mitchell, MSc, Leonardo R. Brandão, MD MSc, Jacqueline ML Halton, MD

Blood (2016) 128 (22): 5025.

https://doi.org/10.1182/blood.V128.22.5025.5025

Published: 2016

Journal Articles

Rationale and Design of a Phase III Single-Arm Multicenter Study of Dabigatran Etexilate for the Secondary Prevention of Venous Thromboembolism in Children

Matteo Luciani, Manuela Albisetti, MD, Ivan Manastirski, Martina Brueckmann, MD, Savion Gropper, MD, Igor Tartakovsky, MD, Bushi Wang, Branislav Biss, Lesley G Mitchell, Fenglei Huang, Jacqueline ML Halton, MD, Leonardo R. Brandão, MD MSc

Blood (2016) 128 (22): 5028.

https://doi.org/10.1182/blood.V128.22.5028.5028

Published: 2016

Journal Articles

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Given after Standard Anticoagulant Therapy in Children (Two Age Groups: 1-<2 and 2-<12 Years Old), with Venous Thromboembolism

Jacqueline ML Halton, MD, Manuela Albisetti, MD, Matteo Luciani, Fenglei Huang, Branislav Biss, Martina Brueckmann, MD, Savion Gropper, MD, Hugo Maas, Igor Tartakovsky, MD, Lesley G Mitchell

Blood (2016) 128 (22): 87.

https://doi.org/10.1182/blood.V128.22.87.87

Published: 2016

NARROW

Dabigatran Etexilate in Children with Venous Thromboembolism: Results of the Open-Label, Phase IIb/III, Randomized Diversity Clinical Trial

Efficacy and Safety of Dabigatran in the Treatment and Secondary Prophylaxis of Children with Venous Thromboembolism and Thrombophilia

Pharmacokinetics (PK) and Pharmacodynamics (PD), Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Etexilate Given after Standard Anticoagulant Therapy in Children from Birth to Less Than One Year Old, with Venous Thromboembolism

Rationale and Design of a Phase III Safety Trial of Idarucizumab in Children Receiving Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism

Rationale and Design of a Phase IIb/III Open-Label, Multicenter Study of Dabigatran Etexilate for Venous Thromboembolism in Children: The Diversity Study

Rationale and Design of a Phase III Single-Arm Multicenter Study of Dabigatran Etexilate for the Secondary Prevention of Venous Thromboembolism in Children

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Given after Standard Anticoagulant Therapy in Children (Two Age Groups: 1-<2 and 2-<12 Years Old), with Venous Thromboembolism

Email alerts

ASH Publications

American Society of Hematology

Dabigatran Etexilate in Children with Venous Thromboembolism: Results of the Open-Label, Phase IIb/III, Randomized Diversity Clinical Trial

Efficacy and Safety of Dabigatran in the Treatment and Secondary Prophylaxis of Children with Venous Thromboembolism and Thrombophilia

Pharmacokinetics (PK) and Pharmacodynamics (PD), Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Etexilate Given after Standard Anticoagulant Therapy in Children from Birth to Less Than One Year Old, with Venous Thromboembolism

Rationale and Design of a Phase III Safety Trial of Idarucizumab in Children Receiving Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism

Rationale and Design of a Phase IIb/III Open-Label, Multicenter Study of Dabigatran Etexilate for Venous Thromboembolism in Children: The Diversity Study

Rationale and Design of a Phase III Single-Arm Multicenter Study of Dabigatran Etexilate for the Secondary Prevention of Venous Thromboembolism in Children

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Given after Standard Anticoagulant Therapy in Children (Two Age Groups: 1-<2 and 2-<12 Years Old), with Venous Thromboembolism

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only